Endocrinology Research Analysis

Mouse genetics and endocrine assays demonstrate that myostatin, secreted from skeletal muscle, acts systemically to directly stimulate pituitary FSH synthesis, establishing a muscle–pituitary endocrine axis that challenges activin’s primacy in FSH regulation and has immediate implications for myostatin-targeting therapeutics.

Impact: Redefines reproductive endocrine hierarchies by uncovering a muscle-to-pituitary axis for FSH control and prompts fertility safety considerations for a drug class in active development.

Clinical Implications: Calls for fertility counseling and monitoring during myostatin antagonism for muscle disorders; may guide dosing or patient selection in reproductive-age populations.

Future Directions: Test endocrine and fertility outcomes under myostatin-targeted therapies in humans and delineate receptor-level pituitary mechanisms and sex-specific effects.

Multi-cohort human datasets identified enrichment of A. tubingensis in PCOS; mouse colonization reproduced PCOS-like metabolic and reproductive phenotypes via AhR inhibition and reduced ILC3-derived IL-22. A metabolite screen pinpointed AT-C1, an endogenous fungal AhR antagonist, establishing a mycobiome→AhR→immune axis causally driving PCOS.

Impact: Opens a new etiologic paradigm for PCOS that is microbiome- and metabolite-targetable, shifting the field toward modifiable exogenous drivers.

Clinical Implications: Supports mycobiome profiling and AhR-restoring strategies as adjuncts to metabolic/ovulatory therapies; motivates development of diagnostics for pathogenic fungal metabolites.

Future Directions: Develop targeted diagnostics for AT-C1 and conduct early-phase trials of AhR agonists or selective fungal depletion in PCOS with immune endpoints.

This foundational atlas maps human hypothalamic neuroendocrine cell types and their spatial organization, enabling mechanistic interrogation of circuits that regulate appetite, thermoregulation, reproduction, and pituitary axes, and standardizing targets for translational neuroendocrinology.

Impact: Provides a high-resolution human resource linking spatial context to function in neuroendocrine control, accelerating precise target discovery.

Clinical Implications: Enables nomination of tissue- and cell-specific therapeutic targets and biomarkers for hypothalamic disorders, informing neuromodulation strategies.

Future Directions: Leverage the atlas for target validation in appetite and reproductive disorders and integrate with in vivo circuit perturbations and imaging.

A selective small molecule binding BMAL1’s PASB domain remodels clock protein conformation, shifts cellular circadian oscillations, and dampens macrophage inflammatory programs, establishing a validated probe that operationalizes core clock druggability.

Impact: Launches tractable circadian pharmacology with direct functional consequences across immunometabolism, catalyzing a new therapeutic class.

Clinical Implications: Supports development of clock-directed modulators for circadian-linked inflammatory and metabolic diseases and phenotype-based patient stratification, pending in vivo PK/PD and safety.

Future Directions: Advance BMAL1 probes to in vivo efficacy/safety studies, expand to other clock nodes, and integrate circadian biomarkers into early trials.

In MASH-driven HCC models, ACLY inhibition reprograms the immunosuppressive tumor microenvironment, enhances anti-tumor immunity, and suppresses tumor growth, establishing ACLY as an actionable immunometabolic node at the metabolism–oncology interface.

Impact: Positions immunometabolism as a tractable axis to convert non-inflamed tumors into immunoresponsive states in metabolically conditioned cancers.

Clinical Implications: Supports clinical testing of ACLY inhibitors to enhance immunotherapy efficacy in MASH-HCC and possibly other immunologically cold, metabolically driven tumors.

Future Directions: Combine ACLY inhibition with checkpoint blockade in biomarker-selected MASH-HCC and map immunometabolic signatures predictive of response.

β-adrenergic lipolysis induces adipose GDF15 via M2-like macrophages, and GFRAL signaling is required for stress-induced anxiety-like behavior, defining an adipose-to-brain endocrine circuit that links peripheral metabolic mobilization to behavior.

Impact: Demonstrates a causal neuroendocrine axis connecting metabolic state to behavior, with implications for metabolic and psychiatric therapeutics.

Clinical Implications: Supports monitoring neuropsychiatric effects when elevating GDF15 therapeutically and exploration of GDF15–GFRAL antagonism for stress-related anxiety.

Future Directions: Test GDF15–GFRAL antagonism in stress-related phenotypes and incorporate neurobehavioral monitoring in metabolic trials elevating GDF15.

This cross-species study identifies Raptin, a peptide cleaved from RCN2 and secreted during sleep, that binds GRM3 in hypothalamic and gastric neurons to suppress appetite and delay gastric emptying via PI3K–AKT signaling; human data link impaired Raptin secretion to night eating and obesity.

Impact: Defines a druggable sleep–appetite endocrine axis (Raptin–GRM3), reframing obesity therapeutics around sleep physiology.

Clinical Implications: Prioritizes sleep optimization and nominates Raptin analogs/GRM3 agonism for anti-obesity development pending safety evaluation.

Future Directions: Develop Raptin analogs/GRM3 agonists and assess efficacy and safety in obesity and night-eating phenotypes; explore sleep-state–guided dosing.

Minor intron splicing defects trigger Insig1/2 intron retention, SREBP1c activation, and IDH1-dependent reductive carboxylation, fueling lipogenesis and ammonia accumulation to initiate fibrosis. Targeting IDH1, clearing ammonia, or restoring splicing mitigated fibrosis in models, defining a splicing–metabolism checkpoint for MASH.

Impact: Connects RNA processing to metabolic rewiring and fibrosis with multiple actionable nodes (IDH1, ammonia handling, splicing restoration).

Clinical Implications: Prioritizes development of IDH1 inhibitors and ammonia-lowering approaches and minor intron retention biomarkers for antifibrotic stratification.

Future Directions: Develop assays for minor intron retention as biomarkers and test IDH1/ammonia-targeted strategies in early MASH with antifibrotic endpoints.

Massively parallel reporter assays and CRISPR epigenome editing mapped PCOS regulatory elements, demonstrating that upregulation of endogenous DENND1A elevates testosterone in adrenal models, linking noncoding regulatory variation to hyperandrogenism.

Impact: Provides a functional causal bridge from GWAS noncoding variants to a core endocrine phenotype, enabling mechanism-based target discovery in PCOS.

Clinical Implications: Supports genetic risk stratification and DENND1A-centered interventions to reduce hyperandrogenism in PCOS.

Future Directions: Define tissue-specific DENND1A regulation in ovary and test pharmacologic modulators that normalize androgen output.

Cryo-EM and in vivo models show adipogenin selectively binds dodecameric seipin, bridging and stabilizing subunits to promote lipid-droplet biogenesis. Mouse genetics link Adig to adiposity and brown-fat triglyceride storage, providing a structural basis to modulate lipid storage.

Impact: Delivers a high-resolution structural mechanism for lipid storage with in vivo validation, opening druggable axes for lipodystrophy and obesity biology.

Clinical Implications: Suggests Adig–seipin modulation as a translational strategy for lipid-storage disorders, pending human validation and safety profiling.

Future Directions: Design small molecules or biologics that modulate Adig–seipin interactions and evaluate efficacy in lipodystrophy and obesity models.